NO20080585L - Immunologisk adjuvansemulsjon - Google Patents

Immunologisk adjuvansemulsjon

Info

Publication number
NO20080585L
NO20080585L NO20080585A NO20080585A NO20080585L NO 20080585 L NO20080585 L NO 20080585L NO 20080585 A NO20080585 A NO 20080585A NO 20080585 A NO20080585 A NO 20080585A NO 20080585 L NO20080585 L NO 20080585L
Authority
NO
Norway
Prior art keywords
oil
emulsion
nonionic surfactant
adjuvant emulsion
relates
Prior art date
Application number
NO20080585A
Other languages
English (en)
Other versions
NO336369B1 (no
Inventor
Marie-Francoise Klucker
Francois Dalencon
Patricia Probeck-Quellec
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0507240A external-priority patent/FR2888117B1/fr
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of NO20080585L publication Critical patent/NO20080585L/no
Publication of NO336369B1 publication Critical patent/NO336369B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Oppfinnelsen angår en termoreversibel olje-i-vann adjuvansemulsjon omfattende minst: skvalen; et vandig løsningsmiddel; en ikke-ionisk surfaktant som er i fonn av en polyoksyetylenalkyleter; og en hydrofob ikke-ionisk surfaktant, der 90 % av populasjonen basert på volumet av oljedråpene er mindre enn 200 nm i størrelse. Oppfinnelsen angår også en fremgangsmåte for å fremstille en immunogen sammensetning, der minst et vaksineantigen blandes med en olje-i-vann emulsjon. Oppfinnelsen kjennetegnes ved at olje-i-vann emulsjonen oppnås ved anvendelse av en fremgangsmåte som involverer faseinversjon ved hjelp av temperaturvariasjon.
NO20080585A 2005-07-07 2008-01-31 Olje-i-vann adjuvansemulsjon, anvendelse og fremgangsmåte for fremstilling derav, samt immunogen sammensetning og fremgangsmåte for fremstillling derav. NO336369B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0507240A FR2888117B1 (fr) 2005-07-07 2005-07-07 Composition vaccinale comprenant une emulsion thermoreversible
FR0508310 2005-08-04
PCT/FR2006/001635 WO2007006939A2 (fr) 2005-07-07 2006-07-07 Emulsion immuno-adjuvante thermoreversible

Publications (2)

Publication Number Publication Date
NO20080585L true NO20080585L (no) 2008-03-26
NO336369B1 NO336369B1 (no) 2015-08-10

Family

ID=37637538

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080585A NO336369B1 (no) 2005-07-07 2008-01-31 Olje-i-vann adjuvansemulsjon, anvendelse og fremgangsmåte for fremstilling derav, samt immunogen sammensetning og fremgangsmåte for fremstillling derav.

Country Status (24)

Country Link
EP (2) EP2080522B1 (no)
JP (1) JP5300475B2 (no)
KR (1) KR101328638B1 (no)
CN (1) CN101217977B (no)
AR (1) AR054822A1 (no)
AT (1) ATE424845T1 (no)
AU (1) AU2006268466B2 (no)
BR (1) BRPI0614053A2 (no)
CA (1) CA2613732C (no)
CY (2) CY1108994T1 (no)
DE (1) DE602006005671D1 (no)
DK (2) DK2080522T3 (no)
EA (1) EA012376B1 (no)
ES (2) ES2390104T3 (no)
IL (1) IL187967A0 (no)
MX (1) MX2007016412A (no)
NO (1) NO336369B1 (no)
NZ (1) NZ564173A (no)
PL (2) PL2080522T3 (no)
PT (2) PT2080522E (no)
SG (1) SG163584A1 (no)
SI (2) SI1904099T1 (no)
TN (1) TNSN08001A1 (no)
WO (1) WO2007006939A2 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006226459A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2011213757B2 (en) * 2005-11-04 2013-07-25 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
AU2006310336B2 (en) 2005-11-04 2011-02-03 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ567978A (en) * 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
GB0622282D0 (en) * 2006-11-08 2006-12-20 Novartis Ag Quality control methods
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
ES2482192T3 (es) * 2007-05-31 2014-08-01 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Vacunación intradérmica del péptido de HPV
CN101428145B (zh) * 2007-11-05 2013-01-02 北京生泰尔生物科技有限公司 新型疫苗佐剂
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
EP2254594B1 (en) 2008-03-05 2015-06-03 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
CN102170902B (zh) 2008-08-01 2015-07-15 伽玛疫苗有限公司 流感疫苗
CA2751379C (en) 2009-02-10 2018-06-12 Novartis Ag Influenza vaccines with reduced amounts of squalene
PL2400951T3 (pl) * 2009-02-25 2019-02-28 Mayne Pharma Llc Miejscowa kompozycja pianki
KR20120088721A (ko) 2009-10-09 2012-08-08 씨바이오 리미티드 샤페로닌 10 변이체
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB201009673D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 肺炎球菌に対する免疫用組成物
CA2825403C (en) 2011-01-27 2023-02-21 Gamma Vaccines Pty Limited Vaccines comprising a combination of gamma irradiated influenza virus and a further immunogen
EP2578974A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
NZ630807A (en) 2012-03-23 2016-04-29 Pitney Pharmaceuticals Pty Ltd Kinase inhibitors for the treatment of cancer
CA2875683A1 (en) 2012-06-05 2013-12-12 The Australian National University Vaccination with interleukin-4 antagonists
WO2013184900A2 (en) 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
CA2878682A1 (en) 2012-07-24 2014-01-30 Alain Bouckenooghe Vaccine compositions for use in a method of protecting a human subject against dengue disease
AU2013295016A1 (en) 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
NZ631523A (en) 2012-08-06 2017-03-31 Pitney Pharmaceuticals Pty Ltd Compounds for the treatment of mtor pathway related diseases
CN103784953B (zh) * 2012-10-26 2018-04-10 上海医药工业研究院 作为疫苗佐剂的水包油型亚微乳及其制备方法
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
JP6502853B2 (ja) 2012-12-17 2019-04-17 ニューサウス イノベイションズ ピーティーワイ リミテッド ムチンが関与する疾患の処置
US10357538B2 (en) 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
EP3016968B1 (en) 2013-07-01 2019-06-26 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
CN105267963A (zh) * 2014-06-18 2016-01-27 潘皓 纳米乳疫苗辅剂的制备方法
CA2955562C (en) 2014-07-21 2018-05-22 Thomas Gebhard Liquid feeding device for the generation of droplets
EP3273989B1 (en) 2015-03-26 2023-12-27 Gpn Vaccines Pty Ltd Streptococcal vaccine
CN105251002B (zh) * 2015-11-13 2019-02-15 中国人民解放军第三军医大学 一种水包油型纳米乳佐剂及其mrsa纳米乳佐剂疫苗和制备方法
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
WO2017162741A1 (en) * 2016-03-23 2017-09-28 Intervet International B.V. A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection
WO2018030777A1 (ko) * 2016-08-10 2018-02-15 ㈜셀트리온 항-인플루엔자 바이러스 항체의 안정한 액체 약제학적 제제
SG11201908280SA (en) 2017-03-30 2019-10-30 Univ Queensland "chimeric molecules and uses thereof"
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
WO2022046634A1 (en) 2020-08-24 2022-03-03 Sanofi Pasteur Inc. Vaccines against sars-cov-2 infections

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
JP2607712B2 (ja) 1988-01-29 1997-05-07 カイロン コーポレイション 組換えｃｍｖ中和タンパク
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
US6299848B1 (en) * 1998-09-25 2001-10-09 Hamon Research-Cottrell Process for removing sulfur dioxide out of a gas
KR100922031B1 (ko) * 1999-04-19 2009-10-19 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
DE60233934D1 (de) * 2001-03-21 2009-11-19 Madash Llc Thermisch reversible wasser-in-öl-in-wasser-emulsionen
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante

Also Published As

Publication number Publication date
EP1904099B1 (fr) 2009-03-11
CA2613732C (en) 2013-12-10
CN101217977B (zh) 2013-03-06
CA2613732A1 (en) 2007-01-18
DE602006005671D1 (en) 2009-04-23
SG163584A1 (en) 2010-08-30
CN101217977A (zh) 2008-07-09
DK1904099T3 (da) 2009-06-08
EP1904099A2 (fr) 2008-04-02
KR101328638B1 (ko) 2013-11-27
PL2080522T3 (pl) 2012-11-30
SI1904099T1 (sl) 2009-08-31
WO2007006939A3 (fr) 2007-04-05
CY1113414T1 (el) 2016-06-22
EP2080522B1 (fr) 2012-07-04
IL187967A0 (en) 2008-03-20
JP5300475B2 (ja) 2013-09-25
NO336369B1 (no) 2015-08-10
ES2390104T3 (es) 2012-11-06
SI2080522T1 (sl) 2012-10-30
AR054822A1 (es) 2007-07-18
BRPI0614053A2 (pt) 2011-03-09
KR20080030076A (ko) 2008-04-03
NZ564173A (en) 2010-10-29
EA012376B1 (ru) 2009-10-30
EA200800271A1 (ru) 2008-04-28
EP2080522A1 (fr) 2009-07-22
MX2007016412A (es) 2008-03-07
ATE424845T1 (de) 2009-03-15
AU2006268466B2 (en) 2011-11-10
TNSN08001A1 (fr) 2009-07-14
WO2007006939A2 (fr) 2007-01-18
PL1904099T3 (pl) 2009-08-31
ES2322102T3 (es) 2009-06-16
JP2009500382A (ja) 2009-01-08
AU2006268466A1 (en) 2007-01-18
PT1904099E (pt) 2009-05-29
CY1108994T1 (el) 2014-07-02
DK2080522T3 (da) 2012-10-08
PT2080522E (pt) 2012-10-01

Similar Documents

Publication Publication Date Title
NO20080585L (no) Immunologisk adjuvansemulsjon
WO2007052061A3 (en) Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
JP2009500382A5 (no)
BR9510223A (pt) Adjuvante para vacinas utilização de um polissacarideo lipidico processo para preparar uma cacina em emulsão e vacina
AR053833A1 (es) Composicion inmunogenetica
WO2007052155A3 (en) Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
DK2268823T3 (da) Fremstilling af squalen ud fra hyperproducerende gærarter
PT1117421E (pt) Novos metodos para vacinacao terapeutica
WO2007052058A8 (en) Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EA200901161A1 (ru) Вакцина против гриппа в виде эмульсии типа "масло в воде"
WO2007024941A3 (en) Polyvalent vaccine
WO2006127454A3 (en) Oil-in-water capsule manufacture process and microcapsules produced by such process
RU2019122996A (ru) Комбинированная вакцина для свиней
WO2006071989A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
ATE423828T1 (de) Herstellungsverfahren für flüssigkristall- emulsionszusammensetzungen
ATE412040T1 (de) Herstellungsverfahren für flüssigkristall- emulsionszusammensetzungen
Kumar Immunizations following solid-organ transplantation
DE3473825D1 (en) Method of preparing adjuvanted live vaccines and adjuvanted live vaccines thus obtained
Harmsen et al. Stabilizing effects of excipients on dissociation of intact (146S) foot-and-mouth disease virions into 12S particles during storage as oil-emulsion vaccine
NO20081033L (no) Redusering av interferens mellom oljeinneholdende adjuvanser og surfaktantinneholdende antigener
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
DE60107073D1 (de) Verfahren zum herstellen einer monodisperse doppelemulsion
NO20070195L (no) Vaksine mot HPV16 og HPV18 og minst en annen HPV-type valgt fra HPV31, 45 eller 52
WO1999002132A3 (en) Use of submicron oil-in-water emulsions with dna vaccines
WO2006091455A3 (en) Molecular scaffolds for hiv-1 immunogens

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees